Ratings for AnaptysBio (NASDAQ:ANAB) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table ...

AnaptysBio stock zoomed higher Wednesday after announcing a $100 million offering that includes participation from pharma ...

AnaptysBio ANAB underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick overview of their recent ...

On Thursday, H.C. Wainwright analyst Emily Bodnar increased the price target on AnaptysBio (NASDAQ:ANAB) shares to $22.00, up from the previous $19.00, while maintaining a Neutral rating on the stock.

JPMorgan raised the firm’s price target on AnaptysBio (ANAB) to $42 from $36 and keeps an Overweight rating on the shares. The firm updated models in the Smid-cap biotechnology group.

https://www.tipranks.com/news/the-fly/medtronic-price-target-raised-to-93-from-89-at-truist Truist notes that AnaptysBio (ANAB) reported the “much anticipated ...

San Diego-based AnaptysBio Inc. (NASDAQ: ANAB) handled the drug's research and development stage. Vanda will pay AnaptysBio a total $15 million: $10 million upfront and another $5 million for its ...

Has AnaptysBio, Inc. (ANAB) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Wedbush in a report issued on Wednesday,RTT News reports.

AnaptysBio, Inc. (ANAB) shares rallied 30.5% in the last trading session to close at $16.15. This move can be attributable to notable volume with a higher number of shares being traded than in a ...